Nordea Investment Management AB Increases Stake in Organon & Co. $OGN

Key Points

• Nordea Investment Management AB increased its stake in Organon & Co. by 1.1%, owning 4,904,076 shares valued at approximately $48.3 million as of the end of the second quarter.
• Organon & Co. reported revenue of $1.59 billion for the last quarter, exceeding analyst expectations and achieving earnings of $1.00 per share.
• The company has recently paid a quarterly dividend of $0.02, with an annualized yield of 0.9%, while the stock currently has a market capitalization of $2.41 billion.

Nordea Investment Management AB boosted its position in shares of Organon & Co. (NYSE:OGN - Free Report) by 1.1% during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 4,904,076 shares of the company's stock after purchasing an additional 53,733 shares during the quarter. Nordea Investment Management AB owned about 1.89% of Organon & Co. worth $48,281,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of OGN. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Organon & Co. by 870.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 1,010,789 shares of the company's stock valued at $15,051,000 after purchasing an additional 906,675 shares during the last quarter. Massachusetts Financial Services Co. MA grew its position in Organon & Co. by 8.3% during the 1st quarter. Massachusetts Financial Services Co. MA now owns 10,715,445 shares of the company's stock valued at $159,553,000 after purchasing an additional 820,378 shares during the last quarter. Goldman Sachs Group Inc. lifted its stake in Organon & Co. by 126.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,435,198 shares of the company's stock valued at $21,370,000 after acquiring an additional 801,307 shares during the period. Gotham Asset Management LLC lifted its stake in Organon & Co. by 74.3% during the 1st quarter. Gotham Asset Management LLC now owns 1,400,250 shares of the company's stock valued at $20,850,000 after acquiring an additional 596,936 shares during the period. Finally, Nuveen LLC bought a new position in Organon & Co. during the 1st quarter valued at about $8,773,000. 77.43% of the stock is owned by hedge funds and other institutional investors.

Organon & Co. Price Performance

OGN opened at $9.28 on Friday. The company has a debt-to-equity ratio of 11.98, a quick ratio of 1.13 and a current ratio of 1.65. The stock has a market capitalization of $2.41 billion, a P/E ratio of 3.45, a P/E/G ratio of 0.84 and a beta of 0.63. The company's 50-day simple moving average is $9.93 and its two-hundred day simple moving average is $10.02. Organon & Co. has a 52-week low of $8.01 and a 52-week high of $19.05.

Organon & Co. (NYSE:OGN - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The company reported $1.00 earnings per share for the quarter, topping the consensus estimate of $0.94 by $0.06. Organon & Co. had a net margin of 11.15% and a return on equity of 163.88%. The firm had revenue of $1.59 billion for the quarter, compared to analysts' expectations of $1.55 billion. During the same quarter in the prior year, the business earned $1.12 EPS. The business's quarterly revenue was down .8% on a year-over-year basis. Organon & Co. has set its FY 2025 guidance at EPS. As a group, analysts predict that Organon & Co. will post 3.68 EPS for the current year.

Organon & Co. Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, September 11th. Stockholders of record on Friday, August 15th were paid a $0.02 dividend. This represents a $0.08 annualized dividend and a dividend yield of 0.9%. The ex-dividend date was Friday, August 15th. Organon & Co.'s dividend payout ratio is 2.97%.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a "sell (d+)" rating on shares of Organon & Co. in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, Organon & Co. presently has an average rating of "Moderate Buy" and a consensus price target of $17.33.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.